New book by Larry Connors Click here Improve your trading - See how
VIAject is an investigational ultra-rapid-acting injectable human insulin which Biodel is developing as a treatment for diabetes.
The company said that in a poster presentation at the American Diabetes Association 69th Scientific Sessions, Dr. Roderike Pohl and colleagues from Biodel described results of in vitro studies to explain VIAject's mechanism of absorption and rapid onset of action (poster #438, Rapidity of Hexameric Dissociation of Various Prandial Insulin Formulations). VIAject was shown to have a smaller mean particle size compared to rapid acting insulin analogs and regular human insulin. These data are consistent with an increased proportion of monomeric/dimeric insulin after injection into the subcutaneous space, a key contributor to VIAject's more rapid absorption that has been previously demonstrated in clinical studies.
In a separate presentation on Saturday, Dr. Thomas Forst and colleagues from the Institute for Clinical Research and Development (ikfe), Mainz, Germany, described results of a clinical study comparing the effect of VIAject to regular human insulin and insulin lispro on markers of oxidative stress and endothelial function following a liquid test meal in patients with type 2 diabetes (poster #1304, Postprandial Vascular Effects of VIAject Compared with Insulin Lispro and Regular Human Insulin in Patients with Type 2 Diabetes Mellitus). VIAject was found to be the most effective of the three insulins in reducing post-prandial oxidative stress and improving microvascular blood flow and function. These findings were presented previously at the Eighth Annual Diabetes Technology Meeting in November 2008.
The two posters are available online at biodel.com
Dr. Solomon Steiner, chairman and chief executive officer of Biodel, said: "These poster presentations support our belief that VIAject has unique pharmacologic attributes and clinical effects which make it a very promising drug candidate for the treatment of diabetes. Our VIAject characterization work demonstrated meaningful differences between VIAject and other insulins which may explain its more rapid absorption profile, while measures of oxidative stress and tissue blood flow in patients receiving three different insulin therapies favored VIAject. These findings are encouraging and suggest to us that VIAject has significant clinical and commercial potential as a treatment for diabetes.
"I also wish to congratulate our board member and good friend, Dr. Daniel Lorber, on his receipt of the ADA's Outstanding Physician Clinician in Diabetes Award. Dr. Lorber is a well-known expert on the treatment of diabetes, a former member of the ADA board of directors, and very deserving of this prestigious honor."
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of treatments for endocrine disorders, such as diabetes and osteoporosis.
((Comments on this story may be sent to health@closeupmedia.com))
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
